Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00552071 · ClinicalTrials.gov registry record · Phase 4
Ultrasound Guided Octreotide LAR Injection in Acromegaly
A Phase 4 study, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT00552071 is a Phase 4 study that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 15 participants.
The verdict
NCT00552071, a Phase 4 study, has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
Approximately half of patients with acromegaly do not respond to treatment with somatostatin receptor ligands such as octreotide LAR. This may be due to inadequate drug delivery if the standard of care regular injection is inaccurately delivered in the intramuscular (IM) compartment. Ultrasound guidance of IM injections may improve accuracy of placement of IM injections and increase drug levels, thereby improving efficacy of octreotide LAR for the treatment of acromegaly. The purpose of this study is to determine whether octreotide LAR drug levels differ if given by ultrasound-guided IM injection or by regular IM injection in patients with acromegaly.
Interventions
- DRUG Octreotide LAR 30 MG Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2007-07 |
| Est. Completion | 2014-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00552071
The ClinicalTrials.gov registry entry for NCT00552071 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Octreotide LAR 30 MG Injection is the first listed.
NCT00552071 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00552071 about?
NCT00552071 is a clinical study titled "Ultrasound Guided Octreotide LAR Injection in Acromegaly". Approximately half of patients with acromegaly do not respond to treatment with somatostatin receptor ligands such as octreotide LAR. This may be due to inadequate drug delivery if the standard of care regular injection is inaccurately delivered in the intramuscular (IM) compartment. Ultrasound guid...
What is the current status of trial NCT00552071?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2007-07. Estimated completion is 2014-03.
What interventions are being tested in trial NCT00552071?
The interventions under investigation include: Octreotide LAR 30 MG Injection (DRUG).
Who is sponsoring clinical trial NCT00552071?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.